

Saturday April 14th, 2018
14:30-16:30

POSTERS DISCUSSION SESSIONS

Poster Area

14:30-15:30

Poster Session 1: Biomarkers / Hypercoagulability

Chair: E. Castoldi (the Netherlands)

PO-01 - The combination of podoplanin expression levels and IDH1 mutation status predicts VTE risk in patients with brain tumors

P.M.S. Nazari, J. Riedl, M. Preusser, F. Posch, J. Thaler, C. Marosi, P. Birner, G. Ricken, J.A. Hainfellner, I. Pabinger, C. Ay (*Austria*)

PO-02 - Marked elevation in plasma factor VIII and VWF levels following neoadjuvant chemotherapy, radiation and major cancer surgery

M. Cunningham, M. Byrne, J. Reynolds, B. White, J. O'Sullivan, J.S. O'Donnell (*Ireland*)

PO-03 - Thrombin generation predicts for early recurrence in breast cancer patients undergoing post-surgical adjuvant therapy: results from the HYPERCAN study

C. Giaccherini, M. Marchetti, C. Verzeroli, G. Masci, L. Celio, B. Merelli, R. Sarmiento, S. Brevi, S. Gamba, V. Milesi, D. Raffaeli, L. Russo, C.J. Tartari, P. Malighetti, D. Spinelli, F. De Braud, R. Labianca, G. Gasparini, A. Santoro, F. Giuliani, and A. Falanga on behalf of the HYPERCAN investigators (*Italy*)

PO-04 - The impact of FGG rs2066865 and pre-cancer fibrinogen concentration on cancer-related venous thromboembolism (VTE)

B.Paulsen, O. V. Gran, H.Skille, E. N. Smith, S. K. Brækkan, T. Solomon, F. R. Rosendaal, K. A. Frazer, J. Hansen (*Norway, the Netherlands, USA*)

PO-05 - Joint effects of GP6 rs1613662 and pre-cancer platelet count on the risk of venous thromboembolism in cancer

H. Skille, O. V. Gran, B. Paulsen, E. N. Smith, S. K. Brækkan, T. Solomon, F. R. Rosendaal, K. A. Frazer, J. Hansen (*Norway, the Netherlands, USA*)

PO-06 - Evidence for the role of procoagulant stromal fibroblasts in the progression of Ductal Carcinoma in Situ

G. Farnie, H. Shaker, J. Castle, C.C. Kirwan (*United Kingdom*)

PO-07 - Prothrombotic dominance in patients with chronic cerebrovascular diseases comorbided with myeloproliferative neoplasms

E. Roitman, M. Tanashyan, A. Shabalina, I. Kolesnikova, S. Roumiantsev (*Russia*)

PO-08 - Hemostatic biomarkers levels for the identification of cancer patients at higher VTE risk enrolled in the HYPERCAN study

C. Verzeroli, M. Marchetti, C. Giaccherini, G. Masci, L. Celio, B. Merelli, R. Sarmiento, M. Ghilardi, S. Brevi, S. Gamba, V. Milesi, D. Raffaeli, L. Russo, C.J. Tartari, P. Malighetti, D. Spinelli, A. Santoro, F.

De Braud, R. Labianca, G. Gasparini, F. Giuliani, S. Barni, A. D'Alessio and A. Falanga ¹ on behalf of the HYPERCAN investigators (*Italy*)

PO-09 - The diagnostic potential of 'high normal' platelet counts for identifying cancer in primary care
S.E.R. Bailey, E. Ankus, S. Price, G. Pula, W. Hamilton (*USA*)

PO-10 - Predictors of cancer-associated thrombosis in gastro-intestinal cancer: preliminary results
E. Campello, M. Henderson, A. Ilich, L. Spiezia, D.F. Noubouossie, N. Mackman, C. Bulato, C. M. Radu, S. Rampado, R. Bardini, N.S. Key, P. Simioni (*Italy, USA*)

PO-11 - Fibrinogen, D-Dimers and thrombin generation assays as predictors of the risk of recurrent VTE in patients with gynaecological malignancies.
Z. Marchocki, N. Gleeson¹, F. Abu Saadeh, M.P Ward, S.A. O'Toole, L.A. Norris (*Ireland*)

15:30-16:30

Poster Session 2: Treatment of thrombosis in cancer

Chair: A.J. ten Cate-Hoek

PO-12 - Recurrence of venous thromboembolism among non small cell lung cancer patients treated with EGFR inhibitors
V. Varchetta, C. Campanella, A. Caggiati, L. Granati, R. Brandi, M. Vitale, G. Soda and A. Mancuso Petricca (*Italy*)

PO-13 - Prophylaxis and treatment of venous thromboembolism: data on a survey amongst members of the Spanish Medical Oncology Society.
C. Font, I. García-Escobar, O. Madridano, M. L. Sánchez Lorenzo, M. Pilar Ochoa Rivas, J. Muñoz Langa, A. Rodriguez Garzotto, M. Martin Pozo, R. Luque Caro, J. Calzas, J. Martinez-Galán, E. Martinez de Castro, A. Hernández, M. Dorta, A. Gomez de Liaño, C. Salvador-Coloma, R. Mondéjar, A. Belén Rupérez and A. Muñoz (*Spain*)

PO-14 - Clinical dilemmas with cancer-associated splanchnic venous thrombosis in current oncological practice: a case study
Adrián García-Villa, Mario Pagès, Tamara Saurí, Iván Victoria, Gustavo Ruiz, Carmen Díaz-Pedroche, Carme Font (*Spain*)

PO-15 - Effectiveness and safety of rivaroxaban versus warfarin for treatment of cancer-associated venous thrombosis
C.I. Coleman, T.J. Bunz, C.G. Kohn, J. Beyer-Westendorf (*United Kingdom*)

PO-16 - Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: A systematic review
B. Samuleson Bannow, A. Lee, A. Khorana, J. Zwicker, S. Noble, C. Ay, M. Carrier (*Canada*)

PO-17 – Long-term treatment bemiparin in patients with Cancer-Associated Venous Thromboembolism. ELEBAMA study
P. Pascual Elena, A. Rebollo Maite, P. Vidal Joan, R. Palmer Elena, D. Santasusana Pere (*Spain*)

PO-18 - Assessing physician adherence to clinical practice guidelines in the management of cancer-associated venous thromboembolism: a retrospective analysis from a tertiary care centre in

Canada

M. Bernstein, I. Barrera, J. Ranger, H. Rho, P. Kavan (*Canada*)

PO-19 - Systematic review and meta-analysis of real-world studies evaluating rivaroxaban for cancer-associated venous thrombosis

B.K. Martinez, J. Sheth, N. Patel, W.L. Baker, C.I. Coleman (*USA*)

PO-20 - Treatment Outcomes of Cancer Associated Venous Thrombosis; The Cleveland Clinic Experience

D. Angelini, S. Rahman, S. Poudel, T. Radivoyevitch, M. Wilks, V. Pinkava, M. O'Brien, B. Tripp, J.M. Song, K. McCrae, A.A. Khorana (*USA, Canada*)

PO-21 - Patient and carer experience of oral and injected anticoagulation for cancer-associated thrombosis: select-d trial qualitative sub-study

A. Hutchinson, S. Rees, A. Young, A. Maraveyas, K. Date and M.J. Johnson (*United Kingdom*)

PO-22 - Cancer Associated Thrombosis and anticoagulation: What is the optimal approach?

N. Pandit, P. Handa (*Republic of Singapore*)

14:30-15:30

Poster Session 3: Clinical challenges

Chair: M. Panova-Noeva (*Germany*)

PO-23 - Non-bacterial endocarditis as an initial presentation of a Trousseau's Syndrome? A complex diagnostic challenge. Case report

A.B. Vilaseca, S. Pastoriza, M. Ameida (*Argentina*)

PO-24 - Rare localization thrombosis as manifestation of occult cancer: clinical case

A.Vorobev, A. Makatsaria (*Russia*)

PO-25 - Cancer diagnosis as a risk factor of ischemic stroke in atrial fibrillation patients with low stroke risk score

A. Atterman, B. Gigante, K. Asplund, S. Aspberg (*Sweden*)

PO-26 - Retinal vein thrombosis and risk of cancer: A population-based cohort study

A.T. Hansen, K. Veres, P. Prandoni, K. Adelborg, H.T. Sørensen (*Denmark, Italy*)

PO-27 - Chronic thromboembolic pulmonary hypertension in cancer patients with pulmonary embolism

J. Catella-Chatron, A. Merah, E. De Magalhaes, N. Moulin, S. Accassat, C. Duvillard, P. Mismetti, L. Bertolotti (*France*)

PO-28 - Threatened abortion and risk of cancer

E. Dudukina, D. K. Farkas, E. Horváth-Puhó, P. Prandoni, H.T. Sørensen, and V. Ehrenstein (*Denmark, Italy*)

PO-29 - Venous thrombosis and lymphoma : a monocentric reports of 13 cases

Z. Tazi-Mezalek, O. Ahrikat, M. Bourkia, W. Ammouri, A. L'housni, M. Boulouad, H. Khibri, M. Maamar, H. Harmouche, M. Adnaoui (*Marocco*)

PO-30 - Cancer-associated splanchnic venous thrombosis: clinical findings at presentation

A. García-Villa, R. Yarza, M. Pagès, C. Díaz-Pedroche, C. Font (*Spain*)

PO-31 - Awareness and understanding of venous thromboembolism in patients with cancer: data on 100 unselected cancer outpatients

B. Nicolau, M. García-Morillo, A. Rodriguez, A. García-Villa, K. S. Cortes, C. Calderon, C. Beato, L. J. Palomares, R. Otero, P. Gascon, M. Monreal and C. Font (*Spain*)

PO-32 - Effect of ischemic conditioning in patients undergoing cancer surgery: A systematic review.

K. Frederiksen, A.E. Krag, J.B. Larsen, A.M. Hvas (*Denmark*)

PO-33 - Patient, tumour and operative factors influencing perioperative hypercoagulability in colorectal cancer

P.A. Rees, H.W. Clouston, H. Shaker, J. Castle, S. Duff, C.C. Kirwan (*United Kingdom*)

15:30-16:30

Poster Session 4: Epidemiology and thrombotic risk factors

Chair: P. Simioni (*Italy*)

PO-34 - Increased risk of venous thromboembolism (VTE) and shorter survival in neuroendocrine versus castration-resistant prostate cancer

C. Jakubowski, P.J. Vlachostergios, P. Christos, D.M. Nanus, H. Beltran, S.T. Tagawa (*USA*)

PO-35 - Retrospective cohort study of venous thromboembolism rates in ambulatory cancer patients, association with Khorana score and other risk factors

K. Austin, J. George, E.J. Robinson, M. Scully, M.R. Thomas (*United Kingdom*)

PO-36 - Clostridium difficile infection is Risk factor of Portal Vein Thrombosis in Hepatocellular Carcinoma Patients

A. Kurniawan, N. Pratama Hardjo Lugito (*Indonesia*)

PO-37 - Venous Thromboembolic Complications in Patients with Ovarian Cancer compared to Patients with Benign Ovarian Tumours

H. Strøm Kahr, A. Knudsen, O. B. Christiansen, A. Grove, V. Iyer, O. Thorlacius-Ussing (*Denmark*)

PO-38 - Risk and prognosis of cancer after upper-extremity deep venous thrombosis: A population-based cohort study

K. Adelborg, E. Horváth-Puhó, J. Sundbøll, P. Prandoni, A. Ording, H. Toft Sørensen (*Denmark*)

PO-39 - Clinical case of thrombosis of rare localization in pregnant women with hidden ovarian cancer

A. Vorobev, A. Makatsaria (*Russia*)

PO-40 - In patients with cancer, prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE. A prospective cohort study in 3032 cancer patients with central venous catheter (ONCOCIP)

H. Decousus, L. Bertoletti, P. Fournel, A. Bourmaud, C. Labruyère, E. Presles, A. Merah, S. Laporte, L. Stefani, G. Landry, F. Chauvin, G. Meyer; for the ONCOCIP Study Group (*France*)

PO-41 - Venous Thromboembolic Complications in Patients with Cancer Corpus Uteri

H. Strøm Kahr, O. Thorlacius-Ussing, O. B. Christiansen, A. Grove, C. Torp-Pedersen, A. Knudsen (*Denmark*)

PO-42 - Epidemiologic study of patients with thrombotic events referred to Dastgheib Thrombosis and Hemostasis Research Center in south of Iran (2015-2017)

A. Akbari, M. Karimi (*Iran*)

PO-43 - Lymphoma under hospitalized chemotherapy schemes: Specific Thromboembolic Risk Factors and Venous thrombosis incidence

C. Sánchez-Martín, O. Benitez, C. Díaz-Aizpun, P.G. Martín, M. Espeso de Haro, M.E. Mingot-Castellano (*Spain*)

PO-44 - Incidence of venous thromboembolism in childhood acute leukemia patients - tertiary care centre experience from kingdom of SAUDI ARABIA

M. AlSaleh, A. Aljefri, A. AlAhmari, H. AlSaedi, A. AlSeraihy, N. Farhan, S. Jose, B. Safi, R. Jafri, V. Mohammed, S. AlSweedan (*Saudi Arabia*)

PO-45 - High Incidence of Venous Thromboembolism in Children and Adolescents with Hodgkin's Lymphoma

D. Evstratov, P. Zharkov, N. Myakova (*Russia*)

14:30-15:30

Poster Session 5: Anticoagulants and cancer

Chair: M. Huisman (the Netherlands)

PO-46 - 30-day mortality in cancer patients with atrial fibrillation and bleeding following treatment with warfarin or non-vitamin K oral antagonists

A.G. Ording, K. Veres, K. Adelborg, H.T. Sørensen (*Denmark*)

PO-47 - Small cell lung cancer patients and venous thromboembolism: The need of anticoagulation treatment

E. Dimakakos, K. Livanios, S. Tsagkouli, S. Tsimboulis, D. Vassos, G. Krommidas, K. Syrigos (*Greece*)

PO-48 - Adverse events of rivaroxaban usage in cancer patients

C. P. Escalante, A. Zalpour, J. Song, M. Richardson, J. Halm, S.W. Yusuf, S. Gao (*USA*)

PO-49 - A case of near fatal pulmonary embolism in a woman with lung cancer

E. Tsaroucha, C. Tzimopoulos, A. Athanassopoulou, E. Ralli, G. Noutsos, E. Kavada, A. Andrianopoulos, A. Rapti (*Greece*)

PO-50 - Direct oral anticoagulants do not inhibit growth and metastasis of human triple negative breast cancer in immunodeficient mice

J.T. Buijs, E.H. Laghman, R.F.P. van den Akker, C. Tieken, E. Vletter, K. van der Molen, J. Crooijmans, C. Kroone, G. van der Pluijm, S.E. le Dévédec, H.H. Versteeg (*the Netherlands*)

PO-51 - The effects of exogenous coagulation factors, and their inhibitors, on in vitro proliferation and migration in colorectal cancer

P.A. Rees, H.W. Clouston, R. Lamb, S. Duff, C.C. Kirwan (*United Kingdom*)

PO-52 - Mural thrombus of ascending aorta successfully managed with anticoagulation in a patient with metastatic cancer

A. Rodríguez, M. García, M. Benegas, B. Mellado, M. Jimeno, C. Font (*Spain*)

PO-53 - Clinical impact of bleeding in cancer-associated venous thromboembolism: results from the Hokusai VTE Cancer randomized trial

N. Kraaijpoel, M. Di Nisio, F. Mulder, N. van Es, M. Carrier, D. Garcia, M. Grosso, A. K. Kakkar, M. F. Mercuri, S. Middeldorp, A. Segers, P. Verhamme, T. Wang, J.I. Weitz, G. Zhang, H. R. Büller, G. Raskob (*the Netherlands, Italy, Canada, United Kingdom, Belgium, USA*)

PO-54 - Tumor cell-induced endothelial pro-thrombotic phenotype is inhibited by heparins

A. Vignoli, M. Marchetti and A. Falanga (*Italy*)

PO-55 - Risk scores for occult cancer in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study

N. Kraaijpoel, N. van Es, G.E. Raskob, H.R. Büller, M. Carrier, G. Zhang, M. Lin, M.A. Grosso, M. Di Nisio (*the Netherlands, USA, Canada, Italy*)

PO-56 - Update for: Thrombin Inhibition Preoperatively (TIP) in Early Breast Cancer, the first clinical trial of DOACs as an anti-cancer agent

J.Castle, J.R. Harvey, R. Clarke, C. Holcombe, A. Volleamere, M. Bramley, J. Kokan, N.J. Bundred, C.C. Kirwan (*United Kingdom*)

15:30-16:30

Poster Session 6: Hemostatic proteins and cancer biology

Chair: G. Taraboletti (*Italy*)

PO-57 - Cell surface GRP78 activation by anti-GRP78 autoantibodies confers prostate tumour growth via tissue factor activation

Ali Al-Hashimi, Bobby Shayegan, Jen Hoogenes and Richard Austin (*Canada*)

PO-58 - Study of the endothelial dysfunction in patients with gastro-intestinal cancer: preliminary results

E. Campello, L. Spiezia, E. Borella, F. Dalla Valle, S. Rampado, R. Bardini, P. Simioni (*Italy*)

PO-59 - Effect of the cleavage of human immunoglobulin G by plasmin on the binding and activation of plasminogen

L.I. Mukhametova, K.B. Gershkovich, R.B. Aisina, E.I Goufman, V.N. Yakovlev (*Russia*)

PO-60 - Cancer cell-derived microvesicles induce endothelial cell apoptosis mediated through tissue factor, factor VII and PAR2 activation

Y. Madkhali, A. Maraveyas, J. Greenman, C. Ettelaie (*United Kingdom*)

PO-61 - Extrinsic pathway markers predict survival in Early Breast Cancer

H. Shaker, J.Y.E. Heah, J. Castle, S. Pritchard, H. Albadry, S. Nicholson, L.J. Lumsden, C.C. Kirwan (*United Kingdom*)

PO-62 - Blood rheology and blood clotting in cancer

I.Tikhomirova, Yu. Malysheva, N.Kislov, M.Ryabov, A.Muravyov (*Russia*)

PO-63 - Genes associated with venous thromboembolism in colorectal cancer patients

B. Ünlü, N. van Es, W. Arindarto, S.M. Kietbasa, H. Mei, J. Westerga, S. Middeldorp, P.J.K. Kuppen, J.M.M.B. Otten, S.C. Cannegieter, H. H. Versteeg (*the Netherlands*)

PO-64 - Extracellular DNA and histones are dispensable for neutrophil extracellular trap-induced aggregation of human washed platelets

O. Elaskalani, N.A. Razak and P. Metharom (*Australia*)

PO-65 - A novel flow cytometry assay using dihydroethidium as redox-sensitive probe reveals NADPH oxidase-dependent generation of superoxide anion in human platelets

A.A. Abubaker, D. Vara, I. Canobbio, G. Pula (*United Kingdom, Italy*)

PO-66 - Extracellular vesicle-associated tissue factor activity is increased in prostate cancer patients with disseminated intravascular coagulation and induced by cellular interactions in vitro

L. Hell, C. Ay, T. Däullary, L.M. Mauracher, E. Grilz, B. Hösel, J. Schmid, I. Pabinger, J. Thaler (*Austria*)

PO-67 - Investigate the regulation of PTEN by tissue factor

A. Mohammad, J. Greenman, A. Maraveyas, C. Ettelaie (*United Kingdom*)

14:30-15:30

Poster Session 7: Thromboprophylaxis and thrombotic risk assessment

Chair: E. De Candia (*Italy*)

PO-68 - First External Validation of the New COMPASS-CAT Risk Assessment Model for Ambulatory Patients with Breast, Colorectal, Lung or Ovarian Cancer.

G.T. Gerotziakas, A.C. Spyropoulos, K. Syrigos, J. Eldredge, L. Anand, S. Nourabadi, D. Rosenberg, L. Papageorgiou, M.G. Qiu, A. Taher, H. Abdel-Razeq, E. AboElnazar, S. El Shemmari, A.K. Larsen, I. Elalamy (*France, USA, Greece, Lebanon, Jordan, Saudi Arabia, Kuwait*)

PO-69 - Neutrophil-to-Lymphocyte Ratio and the Risk of Venous Thromboembolism and Mortality in Patients with Cancer

E. Grilz, F. Posch, O. Königsbrügge, C. Marosi, I. Pabinger, C. Ay (*Austria*)

PO-70 - Validation of the Khorana score in lung cancer patients: a new predictor of early mortality?

I. Vathiotis, E. Dimakakos, P. Boura, A. Ntineri, A.. Charpidou, G.Gerotziakas, K.Syrigos (*Greece*)

PO-71 - Incidence of VTE amongst patients undergoing curative resection for colorectal cancer – an underestimated clinical entity

P.A. Rees, H.W. Clouston, H. Shaker, J. Castle, S. Duff, C.C. Kirwan (*United Kingdom*)

PO-72 - Performance of the RIETE score in an unselected VTE cohort

A. Rosell, S. Lundström, H. Wallén, C. Thålin (*Sweden*)

PO-73 - Can we use the Khorana risk score to predict venous thromboembolism in patients with cancer? A systematic review and meta-analysis

F.I. Mulder; M. Candeloro; N. van Es, M. Di Nisio; H.R. Büller; P.W. Kamphuisen (*the Netherlands, Italy*)

PO-74 - Prospective Assessment of Clinical Risk Factors and Biomarkers of Hypercoagulability for the Identification of Newly diagnosed chemotherapy Naïve Patients with Multiple Myeloma at Risk for Cancer-associated Thrombosis. The Observational ROADMAP-CAT-MM Study.

D. Fotiou, L. Papageorgiou, S. Salta, E.Terpos, J. Fareed, P.VanDreden, E. Lefkou, A.K. Larsen, I. Elalamy, M.A. Dimopoulos, G. Gerotziakas (*France, Greece*)

PO-75 - Patients experience and compliance with extended LMWH prophylaxis post-surgery for gynaecological cancer

Z. Marchocki, L.N. Norris, S. O'Toole, N. Gleeson, F. Abu Saadeh (*Ireland*)

PO-76 - Venous thromboembolism risk assessment of hospitalised cancer patients in a tertiary referral centre

D. Murphy, A. O'Brien, M.I. Khan, C. O'Leary, V. Silvani, S. O'Shea (*Ireland*)

PO-77 - Application of an antithrombotic prophylaxis protocol in patients with multiple myeloma treated with Lenalidomide-Dexamethasone in our center. Thrombosis incidence.

M. Revelles Peñas, I.S. Caparrós Miranda, F.J. Cabrera Ruiz, G. Moreno Carrasco, M. García Fortes, J.J. Ruiz Arredondo (*Spain*)

PO-78 - Characterization of thrombosis risk in patients with cancer

P. Cerezuela, M. Salgado, E. Gallardo, J. Muñoz-Langa, V. Castellón, M. Barbosa, C. Beato, E. Martínez de Castro, V. Martínez, I. García-Escobar, P. Doménech, R. Guijarro, D. Hervás D, M. Merino, Y. de Miguel, E. Colomé, J. Trujillo-Santos (*Spain*)

PO-79 - Superior vena cava syndrome in lung cancer patients: How to prevent its venous thromboembolism complications

E. Dimakakos, F. Micha, A. Charpidou, I. Gkiozos, S. Tsagkouli, M. Kiagia, G. Gerotziakas, K. Syrigos (*Greece*)

15:30-16:30

Poster Session 8: Clinical and diagnostic methodologies

Chair: M. Camera (*Italy*)

PO-80 - Integral assessment of the influence of the generalized tumorous process on the hemostasis indices

I. Vasilenko, A. Balkanov, V. Metelin, Z. Kardashova (*Russia*)

PO-81 - Current monitoring of fibrinolytic activation in cancer patients treated with chemotherapy

V. Sukhanov, O. Petrova (*Russia*)

PO-82 - Lower gastrointestinal bleeding and risk of colorectal cancer in users and non-users of low-dose aspirin

F. Schønfeldt Troelsen, D. Körmendiné Farkas, A. Gulbech Ording, S. Friis, R. Erichsen, and H. T. Sørensen (*Denmark*)

PO-83 - Pre-operative systemic coagulation factors as biomarkers in colorectal cancer

P.A. Rees, H.W. Clouston, H. Shaker, J. Castle, S. Duff, C.C. Kirwan (*United Kingdom*)

PO-84 - Risk of recurrence and bleeding with Rivaroxaban among patients with venous thromboembolism and active cancer

M. Sjøgaard, P.B. Nielsen, F. Skjøth, J.N. Kjældgaard, T.B. Larsen (*Denmark*)

PO-85 - Relationship between ultrasonographic findings and post-thrombotic syndrome in cancer associated thrombosis

A. Romera-Villegas, E. Colomé (*Spain*)

PO-86 - What is the real incidence of VTE recurrence in cancer patients. Impact of statistical methodologies. ELEBAMA study

P. P. Elena, A. R. Maite, P. V. Joan, R. P. Elena, D. Santasusana Pere (*Spain*)

PO-87 - Hypercoagulable State as innovative tool for risk assessment and early cancer diagnosis: data from HYPERCAN Prospective Study

S. Gamba, D. Raffaelli, M. Marchetti, L. Russo, C.J. Tartari, C. Giaccherini, C. Verzeroli, V. Milesi, S. Brevi, G. Sampietro, P. Malighetti, D. Spinelli, and A. Falanga (*Italy*)

PO-88 - The action of Erythropoietin on venous thromboembolic events in lung cancer patients

E. Dimakakos, A. Kakavetsi, I. Gkiozos, A. Charpidou, I. Kotteas, P. Boura, E. Ntalakou, K. Syrigos (*Greece*)

PO-89 - Role of ADAMTS5 in non-alcoholic steatohepatitis

H.R. Lijnen, D. Bauters (*Belgium*)

PO-90 - New generation flow-cytometry to measure circulating microvesicles in cancer

E. Campello, C.M. Radu, L. Spiezia, S. Rampado, C. Bulato, R. Bardini, P. Simioni (*Italy*)